Major Depressive Disorders Clinical Trial
Official title:
Efficacy of Transcranial Direct Current Stimulation (tDCS) of Dorsolateral-prefrontal Cortex as an Add-on Treatment for Drug-naïve Major Depressive Disorder: A Randomized, Double-blind, Sham-controlled Trial
NCT number | NCT04497493 |
Other study ID # | tDCS-2020-TJAH |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 22, 2020 |
Est. completion date | March 2023 |
The aim of this study is to assess the efficacy of Transcranial Direct Current Stimulation (tDCS) as an Add-on Treatment for the drug-naïve Major depressive disorder. Meanwhile, evaluate the effect of tDCS on cognitive function of drug-naïve MDD patients. Furthermore, the investigators will examine the changes in cortisol, gut microbiome and some biomarkers. The hypothesis of this study is that tDCS alleviate the depressive symptoms and improve the cognitive function of drug-naïve Major depressive disorder patients with regulating inflammatory response.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | March 2023 |
Est. primary completion date | October 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - a current episode of MDD diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) - age between 18 and 50 years - a total score of HAMD-17 = 17 - take antidepressants less than 3 days - Patients are compliant with treatment according to the judgement of the treating clinician. Participant or guardian has to sign informed consent. The patients' guardians will sign the informed consent on behalf of the participants when the capacity of participants to consent is compromised. Exclusion Criteria: - A history of manic episode - Use of mood stabilizer - History of substance abuse or dependence - Severe somatic diseases that might interfere with regular antidepressant treatment including conditions such as kidney and liver failure, uncontrolled hypertension, cardiovascular, cerebrovascular and pulmonary disease, thyroid disease, diabetes, epilepsy and asthma. - Use of anti-inflammatory medication for longer than 7 days in the last two months preceding the trial - Use of immunosuppressive medication such as oral steroid hormones Women in pregnancy or lactation period |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Anding Hospital | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Tianjin Anding Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change of scores in Hamilton Depression Rating Scale (HAMD)-17 from baseline to week 4. | The main objective is to explore whether tDCS add on SSRI or SNRI will improve the MDD symptoms after 4 weeks of treatment, and investigators assess the scale at baseline and week 1, 2, 3, 4. Hamilton Depression Rating Scale (HAMD)-17 items was used to evaluate the severity of symptoms of depression. A total score of more than 24 may indicate severe depressive symptoms; A score above 17 may be mild to moderate depressive; If the score is less than 7, the patient has no symptoms of depression. The higher the total score of the scale, the more severe the depressive symptoms. | baseline, Week 1, week 2, week 3, week 4 | |
Secondary | The change of scores in Hamilton Anxiety Rating Scale (HAMA) from baseline to Week 4. | The aim is to explore whether tDCS add on SSRI or SNRI will alleviate the severity of anxious symptoms as measured with HAMA after 4 weeks of treatment, and investigators assess the scale at baseline and week 1, 2, 3, 4. Hamilton Anxiety Rating Scale (HAMA) was used to evaluate the severity of anxiety symptoms and the effects of intervention in patients with anxiety and depressive disorders. The total score = 29 may be severe anxiety; = 21, there may be obvious anxiety; = 14, there may be anxiety; more than 7, there may be anxiety; if less than 7, there will be no anxiety symptoms. | baseline, Week 1, week 2, week 3, week 4 | |
Secondary | The change of scores in Pittsburgh Sleep Quality Index (PSQI) from basline to week 8. | The aim is to investigate whether active-stimuli in addition to regular treatment with an antidepressant will improve the sleep quality as measured with Pittsburgh Sleep Quality Index (PSQI) after 4 weeks of treatment compared to sham-stimuli, and investigators assess the scale at baseline and week 4,8. PSQI was used to evaluate the sleep quality of the subjects in the last month. The total score of PSQI ranged from 0 to 21. The higher the score, the worse the sleep quality. | baseline, Week 4, week8 | |
Secondary | The change of scores in quality of life (QOL) from baseline to week 8. | The aim is to investigate whether active-stimuli in addition to regular treatment with an antidepressant will improve the quality of life as measured with quality of life (QOL) after 4 weeks of treatment compared to sham-stimuli, and investigators assess the scale at baseline and week 4,8. The QOL scale evaluates the physical health, mental health, social relations and other aspects of the participants. The higher the score is, the better the quality of life is. | baseline, Week 4, week 8 | |
Secondary | The change of sores in suicidal risk assessment scale from baseline to week 8 | The aim is to investigate whether active-stimuli in addition to regular treatment with an antidepressant will reduce the risk suicide as measured with the suicidal risk assessment scale after 4 weeks of treatment compared to sham-stimuli, and investigators assess the scale at baseline and week 4,8. The higher the score of the suicidal risk assessment scale, the higher the risk of suicide. | baseline, Week 4, week 8 | |
Secondary | The change of scores in Repeatable Battery for the Assessment of neuropsychological Status (Rebans). | The aim is to observe whether active-stimuli in addition to regular treatment with an antidepressant will improve the cognitive function as measured with Repeatable Battery for the Assessment of Neuropsychological Status (Rebans) after 4 weeks of treatment compared to sham-stimuli, and investigators assess the scale at baseline and week 4,8. The higher the score of the scale, the cognitive function is better. | baseline, Week 4, week 8 | |
Secondary | The changes of levels of biomarkers in peripheral blood from baseline to week 4 | The aim is to investigate the change of cortisol level of saliva and intestinal flora as active stimuli in addition to regular treatment with an antidepressant after 4 weeks of treatment compared to sham stimuli, and investigators collect the specimens at baseline and week 4.
Saliva collection tube to collect saliva, collect naturally discharged saliva in a clean test tube (at least 2ml). Saliva was centrifuged under 1500rpm for 15 minutes and the filtrate was cryopreserved at-80 °C. the saliva was analyzed by ELISA kit. Fecal collection: a) intercept the middle part of the sample with a sterile toothpick or fecal sampler (the surface of feces contains exfoliated cells of intestinal mucosa; the outside is easy to be contaminated, and some bacterial DNA begins to degrade after contact with air), take about the size of peanuts and put them into aseptic 2.0mL centrifuge tubes, 3-5 tubes for each sample are taken for backup,and then put into-80 °C cryopreservation after sub-packaging. |
baseline, week 4 | |
Secondary | Adverse events from baseline to week 4 | The aim is to evaluate the adverse effects during the treatment. | week 1, week 2, week 3, week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02972398 -
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
|
N/A | |
Completed |
NCT00855530 -
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT00825019 -
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
|
Phase 3 | |
Completed |
NCT02829671 -
Loneliness and Occurrence of Suicide Attempts and Suicidal Ideas
|
N/A | |
Recruiting |
NCT02681822 -
Multi-center Imaging Genetics Studies in China
|
||
Completed |
NCT00825058 -
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
|
Phase 3 | |
Completed |
NCT01347138 -
Health Care Management for the Elderly in Community Through Screening
|
N/A | |
Completed |
NCT01377896 -
The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours
|
N/A | |
Completed |
NCT02449447 -
Blended Depression Therapy: Cognitive Behaviour Therapy Face-to-face and Via Internet
|
N/A | |
Completed |
NCT06239740 -
Effects of Electroacupuncture on Cognitive Symptoms in Major Depressive Disorder
|
N/A | |
Not yet recruiting |
NCT02942251 -
Relapse Predicting Model for First Episode Depression
|
N/A | |
Recruiting |
NCT02590185 -
MetAbolism vaRiability of VEnLafaxine
|
N/A |